Karpa Health has launched a turnkey telehealth platform available across the United States. The company says the platform arrives as demand accelerates for GLP-1, peptide, and hormone therapies, giving providers a ready-to-use infrastructure for remote care without building their own system.
Karpa Health has officially launched a telehealth platform that is available across the entire United States. The company describes the new offering as a turnkey system, meaning it provides a complete, ready-to-use infrastructure for delivering remote healthcare services. Healthcare providers can adopt the platform without needing to build their own telehealth system from scratch.
The launch coincides with what Karpa Health describes as accelerating demand for GLP-1, peptide, and hormone treatments. According to the company, this growing interest from both patients and providers is driving the need for scalable telehealth solutions that can effectively manage these specialized therapies.
By offering a nationwide reach, Karpa Health aims to make it easier for practitioners to prescribe and monitor these increasingly popular treatments. The platform is designed so that providers can adopt it without having to invest in developing their own telehealth system. The company positions the platform as a way to streamline the delivery of care for GLP-1, peptide, and hormone therapies at a time when patient interest in these treatments is rising.
The platform's nationwide availability means that providers across all states can access the infrastructure. Karpa Health's goal is to remove barriers to entry for practitioners who want to offer telehealth services for these specific therapies. The turnkey nature of the platform suggests that it includes all necessary components for remote patient management, from prescribing to monitoring.
Peptides referenced: GLP-1.
Related reading: FDA Accepts Sandoz Applications for Generic Tirzepatide, Bachem Holding: Does It Deserve a Spot on Your Watchlist?, Novo Nordisk Gets UK Nod for Wegovy Pill; Medicare Broadens GLP-1 Access, What Semaglutide’s Fentanyl Data Should Mean for How We Design the Next OUD Trial.